A retrospective study to explore the efficacy and safety profile of apatinib combined with whole brain radiation therapy for treatment non-small cell lung cancer with symptomatic brain metastases
Latest Information Update: 09 Mar 2021
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenocarcinoma; Brain metastases; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Mar 2021 New trial record
- 31 Jan 2021 Results assessing efficacy and safety profile of apatinib combined with whole brain radiation therapy for treatment non-small cell lung cancer with symptomatic brain metastases, presented at the 2020 World Conference on Lung Cancer.